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Abstract
Functional imaging gives information about physiological heterogeneity in tumours. The utility of functional imaging tests in providing predictive and prog-
nostic information after chemoradiotherapy for both oesophageal cancer and pancreatic cancer will be reviewed. The beneﬁt of incorporating functional im-
aging into radiotherapy planning is also evaluated. In cancers of the upper gastrointestinal tract, the vast majority of functional imaging studies have used 18F-
ﬂuorodeoxyglucose positron emission tomography (FDG-PET). Few studies in locally advanced pancreatic cancer have investigated the utility of functional
imaging in risk-stratifying patients or aiding target volume deﬁnition. Certain themes from the oesophageal data emerge, including the need for a multi-
parametric assessment of functional images and the added value of response assessment rather than relying on single time point measures. The sensitivity and
speciﬁcity of FDG-PET to predict treatment response and survival are not currently high enough to inform treatment decisions. This suggests that a multimodal,
multiparametric approach may be required. FDG-PET improves target volume deﬁnition in oesophageal cancer by improving the accuracy of tumour length
deﬁnition and by improving the nodal staging of patients. The ideal functional imaging test would accurately identify patients who are unlikely to achieve a
pathological complete response after chemoradiotherapy and would aid the delineation of a biological target volume that could be used for treatment
intensiﬁcation. The current limitations of published studies prevent integrating imaging-derived parameters into decision making on an individual patient basis.
These limitations should inform future trial design in oesophageal and pancreatic cancers.
 2016 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Four separate searches were completed on Ovid
MEDLINE in-process and other non-indexed citations and
Ovid MEDLINE 1994 to present. The searches targeted
literature on: (i) oesophageal cancer, chemoradiotherapy
(CRT) and functional imaging; (ii) pancreatic cancer, CRT
and functional imaging; (iii) oesophageal cancer, functional
imaging and target volume deﬁnition; (iv) pancreatic can-
cer, functional imaging and target volume deﬁnition. All
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(http://creativecommons.org/licenses/by/4.0/).articles were excluded. Trials of neoadjuvant chemotherapy
alone or mixed cohorts of chemotherapy and CRT were
excluded if separate analyses of these treatment modalities
were not described. Studies were grouped into those that
carried out functional imaging before CRT, before and dur-
ing CRT, pre- and post-CRT and post-CRT only.Introduction
The utility of functional imaging to predict chemo-
radiotherapy (CRT) treatment response and prognosis or to
deﬁne target volumes for radiotherapy for upper gastroin-
testinal tumours remains uncertain. Functional imaging can
provide information about the heterogeneity of physiolog-
ical properties within tumours. Correlating functional
imaging-derived parameters with treatment response and
long-term treatment outcome may offer a means of risk-
stratifying patients and ultimately guide treatmentCollege of Radiologists. This is an open access article under the CC BY license
J.M. Wilson et al. / Clinical Oncology 26 (2014) 581e596582decisions. Certain physiological parameters are associated
with resistance to radiotherapy.
Physiological processes that can be assessed with imag-
ing techniques include glucose metabolism, cell prolifera-
tion, hypoxia, perfusion and water diffusion. 18F-
ﬂuorodeoxyglucose (FDG) positron emission tomography
(PET), which reﬂects glucose uptake and retention, is by far
the most commonly used functional imaging test.
Both neoadjuvant CRT and deﬁnitive CRT are treatment
options in oesophageal cancer. Deﬁnitive CRT has a 2 year
local failure rate of around 50% [1e3] andmost local failures
occur within the gross tumour volume (GTV) [4]. A patho-
logical complete response (pCR) is seen in 30% of cases after
CRT [5e7]. If rates of pCR could be improved by image-
guided treatment intensiﬁcation, CRT followed by selec-
tive salvage oesophagectomy may become the preferred
treatment. The early identiﬁcation of non-responders
would also deﬁne a group of patients who should proceed
to early surgery.
Locally advanced pancreatic cancer (LAPC) has a poor
prognosis, with a median survival ranging from 5 to 19
months [8]. The LAP07 trial has recently reported that CRT
after induction chemotherapy confers no survival advan-
tage compared with continuing with chemotherapy alone
(overall survival 15.2 and 16.4 months, respectively) [9]. The
failure of CRT to improve treatment outcome is, perhaps, a
little surprising, given that for 25e29% of patients with
LAPC, the ﬁrst site of disease progression is at the site of the
original tumour [10,11]. Escalating the radiotherapy dose to
the pancreas seems attractive, but is limited by normal
tissue toxicity, particularly in the duodenum [12]. If a
method of identifying patients who have a high risk of local
failure could be identiﬁed, a dose-escalation regimen that
allows a higher rate of treatment-associated toxicity may be
seen as worthwhile. After neoadjuvant CRT, those with
<10% of viable tumour cells have a median overall survival
of 39 months compared with only 15 months in those who
have >10% of viable tumour cells remaining [13].
Accurate GTV deﬁnition is essential in radiotherapy
planning to reduce geographical misses and limit the
involvement of normal tissues in the treatment volume.
Incorporating functional imaging into GTV delineation is
attractive for a number of reasons e not least to reduce
intra- and interobserver variability. It may allow an auto-
mation of the target delineation process and identify areas
that may beneﬁt from radiotherapy dose boosting.
Computed tomography is usually used in target volume
delineation for radiotherapy planning. Computed tomog-
raphy has its limitations e most notably in deﬁning medi-
astinal lymph node involvement in oesophageal cancer,
which is improved with FDG-PET.
The utility of functional imaging tests in providing pre-
dictive and prognostic information after CRT for both
oesophageal cancer and pancreatic cancer will be reviewed.
A separate review of the beneﬁt of incorporating functional
imaging into radiotherapy treatment planning will be
included. The limitations of the evidence will be discussed
and recommendations as to how the integration of func-
tional imaging into the risk stratiﬁcation of patients withlocally advanced oesophageal and pancreatic cancers will
be made.
Methods
Four separate searches were completed on Ovid
MEDLINE in-process and other non-indexed citations and
Ovid MEDLINE 1994 to present. The searches targeted
literature on: (i) oesophageal cancer, CRT and functional
imaging; (ii) pancreatic cancer, CRT and functional imaging;
(iii) oesophageal cancer, functional imaging and target
volume deﬁnition; (iv) pancreatic cancer, functional imag-
ing and target volume deﬁnition.
All English language abstracts were reviewed and unre-
lated articles were excluded. Trials of neoadjuvant chemo-
therapy alone or mixed cohorts of chemotherapy and CRT
were excluded if separate analyses of these treatment mo-
dalities were not described. Studies were grouped into
those that carried out functional imaging before CRT, before
and during CRT, pre- and post-CRT and post-CRT only.Results
The database search to identify studies concerned with
treatment response prediction in oesophageal cancer
returned 181 results and three additional studies were
identiﬁed from the references of these studies. Of these,
141 were excluded after full-text review, leaving 43
studies for review. Eighty-one studies concerning target
volume deﬁnition in oesophageal cancer were identiﬁed
by the database search. After full-text review, only 13
were included. The numbers in pancreatic cancer were
lower e the database search identiﬁed 66 studies con-
cerning functional imaging as a means of predicting CRT
response, only six of which were eligible after full-text
review. Only one study using functional imaging to
guide target volume deﬁnition in pancreatic cancer was
identiﬁed by this search strategy. Apart from one series
that used diffusion-weighted magnetic resonance imag-
ing (MRI) [14] and another that used a putative hypoxia
PET tracer (18F-ﬂuoroerythronitromidazole) [15], all series
used FDG-PET as the imaging modality of choice.
Although other functional imaging modalities, such as
dynamic contrast enhanced MRI, have been shown to be
feasible in cancers of the upper gastrointestinal tract [16],
they have not been used in response prediction or target
volume deﬁnition studies.
Tables 1e4 summarise the data that showed a positive
correlation with treatment outcome or prognosis. Many
studies that carried out imaging at more than one time
point commented upon the usefulness of the imaging at
each time point. A clear trend immediately becomes
apparent; imaging before CRT, when analysed indepen-
dently, offers little to no predictive or prognostic informa-
tion [26,33,38,41]. Recent studies that have gleaned as
much information as is possible from pre-CRT FDG-PET by
carrying out a textural analysis have improved upon this to
a degree: one series reported an area under the received
Table 1
Predictive utility of functional imaging in oesophageal cancer
Reference n % pre-
operative
% adenocarcinoma Tumour
radiation dose
and
chemotherapy
agents
Response
assessment
Imaging
modality
Imaging parameter Sensitivity,
speciﬁcity
PPV, NPV
AUC Comments
Imaging at baseline only
[17] 41 0 24 60 Gy (median
dose) in 1.8 Gy
fractions
RECIST: CR versus
non-CR
FDG-PET SUVmax 6 46, 91
e, e
0.7
Carboplatin or
cisplatin/5-FU
SUV
mean 62, 81
e, e
SUV
peak 62, 81
e, e
Local homogeneity 92, 56
e, e
Local entropy 92, 69
e, e
Size zone 92, 69
e, e
0.85
Intensity
variability
85, 75
e, e
[14] 80 14 0 40 Gy in 20
fractions
Cisplatin/5-FU
RECIST: NR versus
PR and CR
DW-MRI ADC < mean
(1.1  103)
86% versus 25%
‘response’ (P < 0.01)
Imaging before and during CRT
[18] 38 100 100 40 Gy in 20
fractions
5-FU
Response ¼ <10%
tumour cells
FDG-PET SUVmax
reduction  30%
after 2 weeks CRT
SUVmax reduction
52% post-CRT
Baseline SUVmax
>3.8
93, 88
93, 88
89, 57
e, e
95, 50
e, e
27/38 had repeat
imaging after 20 Gy (2
weeks)
All 38 had pre- and
post-CRT imaging
[19] 37 100 100 40 Gy in 15
fractions
Cisplatin/5-FU
Mandard TRG FDG-PET SUVmax
reduction  26.4%
63, 72
63, 72
0.674 Imaging before and in
2nd week of CRT
[20] 100 100 82 41.4 Gy in 23
fractions
Carboplatin/
paclitaxel
Mandard TRG FDG-PET 0% SUVmax
reduction
91, 50
76, 75
0.71 AUC for all patients
0.71, adenocarcinoma
0.71, squamous cell
carcinoma 0.35.
Imaging at baseline
and after 2 weeks CRT.
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Table 1 (continued)
Reference n % pre-
operative
% adenocarcinoma Tumour
radiation dose
and
chemotherapy
agents
Response
assessment
Imaging
modality
Imaging parameter Sensitivity,
speciﬁcity
PPV, NPV
AUC Comments
[21] 48 0 0 50 Gy in 25
fractions
Platinum/5-FU
Clinical CR at 3
months
FDG-PET Baseline SUVmax
Baseline metabolic
TV (physician
deﬁned)
>18.6 cm3
50, 87
e, e
0.555
0.701
Imaging at baseline
and 21 days into CRT
Relative change in
parameters offers no
information
Imaging before and after CRT
[22] 36 100 40 Gy in 20
fractions
5-FU
pCR FDG-PET mCR 67, 0
50, e
[23] 83 100 88 50.4 Gy in 28
fractions
Various
regimens
Residual disease FDG-PET Post-CRT PET:
‘abnormal’
SUVmax >2
SUVmax >4
85, 29
e, e
76, 19
e, e
26, 95
e, e
[24] 32 100 100 45.6 Gy in twice
daily 1.2 Gy
fractions or
46 Gy in 23
fractions over 4
weeks
Cisplatin with
5-FU or
capecitabine
pCR FDG-PET mCR
mCR in those with
pre-CRT SUVmax
>4.0
27, 95
75, 71
33, 100
100, 65
[7] 41 100 81 (in cohort of 64
patients)
Median dose
50.4 Gy all
delivered in 1.8
e2.0 Gy
fractions (22
patients
received hyper-
fractionated)
Various
regimens
pCR ormicroscopic
residual disease
FDG-PET Post-CRT SUVmax
<4
61, 60
83, 33
Only 43/64 patients
received CRT and
oesophagectomy.
[25] 62 100 0 45.6 Gy in twice
daily 1.2 Gy
fractions or
46 Gy in 23
fractions
Cisplatin/5-FU
or cisplatin/
capecitabine
pCR FDG-PET mCR 51, 67
79, 64
RR 16.5
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[26] 25 100 88 50.4 Gy in 28
fractions
Various
regimens
Mandard TRG FDG-PET Functional TV
<29 cm3
71, 78
e, e
0.80
Post-SUVmax <4.35 100, 69
e, e
0.82
Post-SUVmean
<3.55
89, 79
e, e
0.85
SUVmean reduction
>32.3%
75, 63
e, e
0.64
[27] 20 100 100 35 Gy in 15
fractions
Cisplatin/5-FU
Mandard TRG FDG-PET
SUVmax reduction
>50%
67, 71
e, e
[28] 51 100 100 50.4 Gy
fractionation
NR
Cisplatin/5-FU
Response ¼ <10%
viable tumour cells
FDG-PET SUVmax reduction
>43%
PET/CT TV
reduction >63%
TLG reduction
>78%
86, 66
64, 87
91, 90
86, 93
91, 93
91, 93
0.843
0.918
TV volume calculated
by PET TL  CT
diameter
[29] 47 100 76 50.4 Gy
fractionation
NR
Cisplatin/5-FU
Response ¼ <10%
viable tumour cells
FDG-PET Functional tumour
length reduction
>33%
SUVmean reduction
>43%
91, 86
e, e
92, 61
e, e
0.919
0.833
[30] 86 100 62 50.4 Gy
fractionation
NR
Cisplatin/5-FU
(for ‘most
patients’)
CR ¼ < 1% viable
tumour
FDG-PET SUVmax reduction
 64%
64, 81
e, e
0.75
[31] 49 100 0 50.4 Gy,
fractionation
NR
Cisplatin/5-FU
Response ¼ <10%
viable tumour cells
FDG-PET “Diameter-SUV
index” reduction
>55%
91, 93
e, e
0.931
SUVmax reduction
> 42%
82, 70
e, e
0.713
[32] 55 100 44 36 Gy in 20
fractions
Cisplatin/5-FU
Response ¼ <10%
viable tumour cells
FDG-PET
SUVmax reduction
of: 22% for AC
50, 90
e, e
0.667
70% for squamous
cell carcinoma
42, 100
e, e
0.698
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Table 1 (continued)
Reference n % pre-
operative
% adenocarcinoma Tumour
radiation dose
and
chemotherapy
agents
Response
assessment
Imaging
modality
Imaging parameter Sensitivity,
speciﬁcity
PPV, NPV
AUC Comments
[33] 37 57 73 50.4 Gy in 28
fractions
Various
regimens
pCR FDG-PET Post-CRT MTV2.5 Post- MTV2.5
correlates with pCR
(P ¼ 0.01). Volume
threshold not
recorded.
[34] 60 100 0 40e45 Gy in
1.8 Gy fractions
Cisplatin/
paclitaxel
pCR FDG-PET Reduction in
functional tumour
length >33%
Reduction SUVmax
>75%
81, 81
75, 84
88, 87
78, 87
[35] 46 48 45 Gy in 25
fractions
Cisplatin/5-FU
Visual (major or
non-major
response)
FDG-PET Pre-SUVmax
Post-SUVmax
DSUVmax
0.573
0.467
0.589
[36] 20 85 50.4 Gy in 28
fractions
Cisplatin/5-FU
Visual FDG-PET SUVmax decline
SUVmax pre/post
Inertia
Correlation
Cluster
predominance
0.76
0.7/0.61
0.85
0.8
0.78
ADC, apparent diffusion coefﬁcient ; AUC, area under the curve; CR, complete response; CT, computed tomography; CRT, chemoradiotherapy; DW-MRI, diffusion-weighted magnetic
resonance imaging; FDG-PET, 18F-ﬂuorodeoxyglucose positron emission tomography; mCR, metabolic complete response; MTV, metabolic tumour volume; NPV, negative predictive
value; NR, not recorded; pCR, pathological complete response; PPV, positive predictive value; PR, partial response; RR, relative risk; TLG, total lesion glycolysis; TRG, tumour
regression grade; TL, tumour length; TV, tumour volume; SUV, standardised uptake value; ; 5-FU, 5-ﬂuorouracil;
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Table 2
Prognostic utility of functional imaging in oesophageal cancer
Reference n % preoperative % adenocarcinoma Total tumour
radiation dose and
chemotherapy agents
Survival end
point
Imaging
modality
Imaging parameter Sensitivity,
speciﬁcity PPV,
NPV %
AUC Comments
Imaging at baseline only
[37] 47 100 87.2 45 Gy or 50.4 Gy,
fractionation NR
Various regimens
Mean OS FDG-PET NPA >1 12.4 versus 19.6
months
Baseline SUV
measurements offer
no prognostic
information. NPA
>1 ¼ lymph node
involvement
[38] 45 0 27 Mean 60 Gy in 1.8 Gy
fractions
Cisplatin/5-FU
OS FDG-PET Functional TV (cut-off
value not recorded)
TLG < 180 g
16 versus 5 months
(P ¼ 0.0005)
21 versus 10 months
(P ¼ 0.01)
[39] 209 0 76 45 Gy in 25 fractions
or 50.4 Gy in 28
fractions
5-FU or capeitabine
with taxane or
platinum
OS FDG-PET SUV < median (12.7) OS 33.4 versus 17.1
months (P ¼ 0.002)
[14] 80 14 0 40 Gy in 20 fractions
Cisplatin/5-FU
1 year
survival
DW-MRI ADC > 1.1  103 18 versus 42 months
(P ¼ 0.02)
Imaging before and during CRT
[18] 38 100 100 40 Gy in 20 fractions
5-FU
OS FDG-PET SUVmax decrease
30% at 2 weeks
38 versus 18 months
(P ¼ 0.01)
[19] 37 100 100 40 Gy in 15 fractions
Cisplatin/5-FU
OS FDG-PET SUVmax decrease
 26.4%
Median OS NS
[40] 59 32 31 66 Gy in 33 fractions
Cisplatin/5-FU
2 year OS FDG-PET Decrease in SUVmax
>30%
83, 34
57, 66
Imaging pre-CRT and
after 20 Gy
>50% 70, 58
63, 65
>70% 36, 83
69, 56
[21] 48 0 0 50 Gy in 25 fractions
Platinum/5-FU
1 year DFS FDG-PET Baseline SUVmax
>11.9
64, 70
e, e
0.670
Baseline metabolic TV
(physician deﬁned)
>14.0 cm3
60, 83
e, e
0.706
Imaging before and after CRT
[22] 36 100 40 Gy in 20 fractions
5-FU
OS FDG-PET Visual ‘major
response’ on post-CRT
imaging
16.3 versus 6.4
months (P ¼ 0.005)
(continued on next page)
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Table 2 (continued )
Reference n % preoperative % adenocarcinoma Total tumour
radiation dose and
chemotherapy agents
Survival end
point
Imaging
modality
Imaging parameter Sensitivity,
speciﬁcity PPV,
NPV %
AUC Comments
[23] 83 100 88 50.4 Gy in 28 fractions
Various regimens
2 year OS FDG-PET Post- SUVmax <4 60% versus 34%
(P ¼ 0.01)
[25] 62 100 0 45.6 Gy in twice daily
1.2 Gy fractions or
46 Gy in 23 fractions
Cisplatin/5-FU or
cisplatin/capecitabine
DFS FDG-PET Decrease in SUVmax
80%
mCR
31.4 versus 17.1
months (P ¼ 0.025)
Not reached versus
17.38 months
(P ¼ 0.006)
For median OS, not
reached versus 22.4
months (P ¼ 0.033)
[26] 25 100 88 50.4 Gy in 28 fractions
Various regimens
DFS FDG-PET Post-SUVmean <4.35 100% DFS during
follow-up versus 53%
recurrence by 9.5
months
[28] 51 100 100 50.4 Gy fractionation
NR
Cisplatin/5-FU
DFS
OS
FDG-PET PET/CT TV reduction
>63%
Mean DFS 29 versus
16 months
(P < 00.001)
Mean OS 34 versus 22
months (P < 0.001)
[29] 47 100 76 50.4 Gy fractionation
NR
Cisplatin/5-FU
DFS FDG-PET Functional tumour
length reduction
>33%
Median DFS 33 versus
19 months (P< 0.001)
[31] 49 100 0 50.4 Gy, fractionation
NR
Cisplatin/5-FU
DFS FDG-PET Reduction the
‘diameter-SUV index’
>55%
Mean DFS 32 versus
16 months (P< 0.001)
[32] 55 100 44 36 Gy in 20 fractions
Cisplatin/5-FU
OS FDG-PET Baseline and relative
reduction in SUVmax
No correlation
[33] 37 57 73 50.4 Gy in 28 fractions
Various regimens
2 year OS FDG-PET Post-
MTV2.5  7.6 cm3
TGA  26.9
84% versus 29% 2 year
OS (P ¼ 0.007)
77% versus 37% 2
years OS (P ¼ 0.04)
[41] 40 0 5 50-55 Gy
Fractionation unclear
Various regimens
OS FDG-PET SUV  2.5 on post-
CRT PET
Hazard ratio (death)
3.56 (95% conﬁdence
interval 1.04e12.15)
Post-CRT imaging only
[42] 53 0 45 50 Gy in 25 fractions
or 35 Gy in 15
fractions
Cisplatin/5-FU
2 year OS FDG-PET mCR (deﬁned as
uptake less than
above/below initial
tumour site or
paramediastinal lung)
32% versus 78%
Relative risk death
increased 5.75 fold
with failure to achieve
mCR
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J.M. Wilson et al. / Clinical Oncology 26 (2014) 581e596 589operator characteristic (ROC) curve of 0.85 when a tech-
nique that calculates the variability in the size and the in-
tensity of homogenous uptake areas within the tumour was
used [17].
It can be seen that studies that have an area under the
curve (AUC) on ROC analysis greater than 0.9 (and therefore
offering relatively robust predictive power) have used a
multi-parametric assessment. Combining functional pa-
rameters with anatomical-derived indices improved the
predictive function of the tests [28,29]. Tests that applied
parameter thresholds based upon ROC curves seem to have
done so to optimise the sensitivity of the test. The appro-
priateness of this approach needs external validation.
Predictive and Prognostic Utility of Functional Imaging in
Oesophageal Cancer
A variety of ways of deﬁning ‘response’ have been used,
with only ﬁve studies using pCR after CRT as the end point
to be predicted [33,22,24,25,34]. The most commonly used
FDG-PET-derived parameter used in response prediction is
the maximum standardised uptake value (SUVmax) - either
as an absolute value at speciﬁc time points or as a relative
change between two scan dates. A number of studies have
shown the failure of SUVmax to predict treatment outcome
or survival [36,38,40]. Parameters that try to include more
information from across a region of interest, such as the
SUVmean, SUVpeak (the average of SUVs clustered around the
SUVmax) or FDG uptake heterogeneity or skewness, have
been shown to offer more predictive information [17,33,36].
Other methods include adding a volumetric measure to the
SUV, such as metabolic tumour volume and total lesion
glycolysis. In oesophageal squamous cell carcinoma (SCC),
the ROC curve AUC improved from 0.71 to 0.93 when a
response in functional tumour volume after CRT was used
rather than SUV assessment alone [31].
SUVmax measured on baseline imaging, when used as an
independent factor, has failed to show any predictive utility
[26,33,38,41]. This is also true when baseline imaging pa-
rameters from studies that used dual time point assess-
ments were analysed independently of the later imaging,
particularly if SUVmax was used [5,23,49]. These data have
not been included in Table 1. Of the 20 studies listed in Table
1 that carried out FDG-PET at two time points, only one
reported an association between baseline SUVmax and
treatment outcome e the ROC curve AUC was 0.555 [21].
Tixier et al. [17] were able to predict the radiological
response using only baseline FDG-PET with a sensitivity of
92% only when textural features such as local homogeneity,
entropy and size zone were calculated. An initial SUVmax
greater than the median value of 12.8 was associated with a
poorer overall survival (17.1 versus 33.4 months; P ¼ 0.002)
in a large retrospective analysis of baseline FDG-PET in
patients treated with CRT as deﬁnitive treatment [39]. An
apparent diffusion coefﬁcient, a parameter derived from
diffusion-weighted MRI, less than the mean was associated
with a radiological response in one series [14].
A metabolic complete response seems to be associated
with a good prognosis. When post-CRT FDG-PET is used in
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J.M. Wilson et al. / Clinical Oncology 26 (2014) 581e596590patients managed by deﬁnitive CRT, metabolic complete
response (deﬁned as a SUVmax < 3) is associated with
improved overall survival and rates of local recurrence
equal to that of patients receiving trimodality therapy [43].
The relative reduction in SUVmax may offer more pre-
dictive information than absolute values [20,34], although
this is not always the case, particularly for those with
adenocarcinoma [27]. A variety of imaging response
thresholds have been used, for example a reduction in
SUVmax ranging from 26.4 to 30% when FDG-PET was
repeated during CRT or from 32.3 to 75% when repeated
post-CRT (see Table 1). However, the sensitivity and speci-
ﬁcity of these tests remain poor.
Tables 1 and 2 demonstrate that in most oesophageal
carcinoma studies, a mixture of adenocarcinoma and SCC
has been included. When adenocarcinoma-only patients
were included, the predictive power of a reduction in
SUVmax from baseline compared with the second week of
CRT no longer provided any prognostic information [19].
This was also observed in a series where a relative reduction
in SUVmax from baseline to post-CRT FDG-PETs showed a
signiﬁcant correlation between a pathological response for
oesophageal SCC but not adenocarcinoma [32]. Only one
study offered different thresholds for adenocarcinoma and
SCC; 22 and 70% reduction in SUVmax, respectively [32]. This
improved the speciﬁcity of the test to 90% for adenocarci-
noma and 100% for SCC.
Hypoxia is a well-known cause of chemoradioresistance.
The SUVmax and SUVmean values on 18F-ﬂuoroerythroni-
tromidazole (FENTIM) PET (a putative hypoxia tracer)
showed good testeretest repeatability, but were not asso-
ciated with a pathological response or survival [15].
Although tumour hypoxia is not just the result of inade-
quate perfusion, a decrease in blood ﬂow on perfusion
computed tomography correlated with tumour size reduc-
tion after CRT. Although a low tumour blood ﬂow was also
associated with a shorter median survival, this cohort had
mixed treatment modalities and as only 12 patients had
CRT, it is difﬁcult to extrapolate these data to the CRT group
[50].
Functional Imaging as a Means of Target Volume Deﬁnition
in Oesophageal Cancer
Incorporating FDG-PET into radiotherapy planning im-
proves the accuracy of target volume deﬁnition and reduces
geographical misses. The degree of agreement between
tumour volumes delineated by different methods is
assessed using a conformality index. A conformality index
of 1.0 indicates total agreement, whereas 0 indicates that
the two volumes are not spatially related at all. Computed
tomography-deﬁned GTVs excluded >5% of the FDG-avid
disease in 61% of patients [51] in one series. In this series,
the conformality index of the GTVs derived from computed
tomography and computed tomography co-registered with
FDG-PET was 0.68. In another series of 16 patients, the
mean conformality index of a computed tomography-
derived and FDG-PET/computed tomography-derived GTV
was 0.46 (range 0.13e0.80) [52].
Table 4
Prognostic utility of functional imaging in pancreatic cancer
Reference n Total tumour
radiation dose and
chemotherapy agents
Survival
end
point
Imaging
modality
Imaging parameter Sensitivity,
speciﬁcity
PPV, NPV %
AUC Comments
[45] NR 50.4 Gy in 28 fractions
or 50 Gy in 40
fractions
Gemcitabine
OS FDG-PET Pre-SUVmax <7.0 Improved median OS
(magnitude NR)
(P < 0.05)
[46] 15 NR TTP FDG-PET SUVmax reduction
>50%
Mean TTP 399 versus
233 days (P < 0.05)
[47] 32 50.4 Gy in 28 fractions
5-FU
OS FDG-PET SUVmax reduction
>63.7%
Median OS 17.0
versus 9.8 months
(P ¼ 0.009)
Median LRPFS 12.3
versus 6.9 months
(P ¼ 0.02)
[48] 30 50.4 Gy in 28 fractions
5-FU
OS FDG-PET FDG-PET CT derived
GTV <91.1 cm3
79.6, 91.7
e , e
0.777 Median OS 14.1
versus 9.5 months
(P ¼ 0.005)
PPV, positive predictive value; NPV, negative predictive value; AUC, area under the curve; 5-FU, 5-ﬂuorouracil; OS, overall survival; FDG-
PET, 18F-ﬂuorodeoxyglucose positron emission tomography; SUV, standardised uptake value; CT, computed tomography; GTV, gross
tumour volume.
TTP.
LRPFS.
J.M. Wilson et al. / Clinical Oncology 26 (2014) 581e596 591The FDG-PET-derived GTVs tended to be smaller than
those outlined on computed tomography alone in some
series [51e54] and signiﬁcantly larger in others [55]. When
a visual assessment of FDG-PET images fused with the
planning computed tomography was integrated into treat-
ment planning, the GTV was decreased by >25% in 12% of
patients and increased by >25% in 6% of patients [56]. The
series by Schreurs et al. [54] showed that 28% of patients
had a >2 cm craniocaudal, anteroposterior or lateral
mismatch between GTVs derived from computed tomog-
raphy and FDG-PET-derived GTV.
FDG-PET improves both intra- and interobserver vari-
ability in GTV deﬁnition for tumours of the gastro-Fig 1. Magniﬁed viewof a trans-axial section through a locally advancedpanc
by two radiation oncologists using only the planning contrast enhanced C
emission tomography (FDG-PET), it can be seen that FDG-avid tissue exten
outlined by 40% of the maximum standardised uptake value (SUVmax; blue)oesophageal junction. The mean interobserver standard de-
viation of tumour length decreased from 10 mm to 8 mm
(P ¼ 0.02) with the addition of FDG-PET/computed tomog-
raphy. This was also true for intraobserver agreement with
themean standard deviation in tumour length reducing from
5.3 mm to 1.8 mm (P ¼ 0.001), with corresponding
improvement in conformity index e 0.73 for PET/computed
tomography versus 0.69 for computed tomography
(P¼ 0.05) [57]. This improvement in interobserver variability
was not replicated in another study, despite the incidence of
geographical miss of FDG-avid disease being reduced [54].
The most obvious way a GTV can be altered by the in-
clusion of PET images is through the inclusion of previouslyreatic adenocarcinoma. Thegross tumour volume (GTV; red)was agreed
T (CECT). Following registration with 18F-ﬂuorodeoxyglucose positron
ds beyond the GTV. A semi-automated process can produce volumes
or 50% of the SUVmax, which may facilitate accurate GTV deﬁnition.
Fig 2. Axial image from 18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) in a patient with locally advanced pancreatic cancer.
An FDG-avid peripancreatic node that was not identiﬁed at the time of diagnostic CECT was detected and included in gross tumour volume
deﬁnition at the time of radiotherapy planning.
Fig 3. Axial images from 18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) in a patient with locally advanced pancreatic cancer.
Although FDG avidity can be used to inform target volume deﬁnition, the process cannot be fully automated. FDG-uptake can be seen to
correspond with a mass within the pancreatic head (A). This area of avidity runs the length of the stent within the common bile duct, including
areas beyond that of the tumour mass (B). FDG avidity is also associated with inﬂammatory cell glucose metabolism.
J.M. Wilson et al. / Clinical Oncology 26 (2014) 581e596592unrecognised involved lymph nodes [55] and a greater ac-
curacy in deﬁning tumour length. An absolute SUV
threshold of 2.36 has been shown to have a sensitivity and
speciﬁcity of 76.2% and 96.0%, respectively, in predicting
positive nodal involvement [58]. Tumour length deﬁned by
an FDG SUV of 2.5 had a better correlation with tumour
length deﬁned by endoscopic ultrasound (EUS) than
computed tomography-deﬁned tumour length. EUS does,
however, seem to be a more robust method of identifying
pathological lymph nodes than FDG-PET [53] and remains
the gold standard.
The timing of FDG-PET is important. In a series that
repeated FDG-PET just before radiotherapy treatment
planning, rather than relying on the diagnostic imaging, new
FDG-avid lymph nodes were identiﬁed in 18% of patients
and 13% had new metastatic disease [59]. The median time
between imaging time points was 22 days in this series.
The best way of segmenting FDG-PET imaging to aid, or
even semi-automate, GTV delineation remains unclear.
Measurement of the tumour at surgical resection has
allowed correlation of a variety of SUV thresholds on FDG-PET with actual measured tumour length [60]. An SUV
that was 40% of the maximum for the tumour grossly
underestimated the tumour length seen after resection.
Another series has suggested that the SUV threshold for
target volume deﬁnition to deﬁne tumour length needs to
be decided on an individual patient basis [61]. In this
analysis, it was found that the optimal SUV threshold used
to deﬁne the tumour varied with tumour length and SUV-
max. For example, long tumours or those with a low SUVmax
required a higher percentage threshold to make the resul-
tant tumour length correlate with that seen at pathology.
This led the authors to conclude that an absolute SUV of 2.5
might be the best compromise if FDG-PET alone was to be
used to deﬁne the cranial and caudal limit of the tumour.
This suggestion was supported by another series where an
FDG SUV of 2.5 correlated very well with tumour length
measured on computed tomography. Using a personalised
SUV threshold based on SUVmax led to a poorer correlation
[62]. Again, although an absolute SUV correlated well with
tumour length, the conformality index of the resultant
volume remained poor (0.57).
J.M. Wilson et al. / Clinical Oncology 26 (2014) 581e596 593The only study to attempt to validate a PET tracer that is
associated with hypoxia to derive target volumes was un-
successful. In a study of 10 patients, the correlation coefﬁ-
cient of the hypoxic volumes derived on two separate
FETNIM-PET studies was only 0.21 [15].
Predictive and Prognostic Utility of Functional Imaging in
Pancreatic Cancer
All studies to assess the predictive and prognostic utility
of functional imaging in pancreatic cancer used FDG-PET.
Only one study that showed a correlation with FDG-PET
parameters with treatment response was found. Higher
baseline SUVmax was associated with a histopathological
response e the predictive function of FDG-PET in this series
was increased by combining the baseline SUVmax with the
relative SUV response after CRT [44]. It should be noted that
this series deﬁned histopathological response as <50%
viable tumour cells seen in a resection specimen. This is
perhaps inevitable given that only 2% achieved a pCR.
Four studies looked for correlation between FDG-PETand
patient prognosis. An association with low baseline SUVmax
and larger SUVmax reduction after CRT was observed (see
Table 4).
Functional Imaging as a Mean of Target Volume Deﬁnition in
Pancreatic Cancer
Only one series has looked at the effect of functional
imaging on GTV deﬁnition in pancreatic cancer. In a cohort
of patients with LAPC, a computed tomography-deﬁned
GTV was used as the reference volume for comparison
with a GTV that was delineated after fusion of the FDG-PET
with the planning computed tomography. An SUV 42% of
SUVmax was used when viewing the FDG-PET. The PET-
derived GTV was larger by 29.7%, due to extension of pri-
mary tumours and additional nodes. Figures 1 and 2 show
the potential beneﬁt of including FDG-PET in radiotherapy
planning for LAPC. Figure 3 illustrates one of the potential
limitations of FDG-PET in LAPC, namely the failure of FDG
uptake to differentiate between tumour glucose meta-
bolism and uptake in inﬂammatory cells. No published data
on the correlation of functional imaging with histopathol-
ogy have been reported.Discussion
Although the aim of this review was to assess the pre-
dictive and prognostic utility and the additional beneﬁt of
functional imaging on target volume deﬁnition in oeso-
phageal and pancreatic cancer, the lack of heterogeneity in
the functional imagingmodalities used and the large degree
of variation in technique and reporting make comparison of
the results challenging.
There is a strong suggestion that a single parameter (e.g.
SUVmax) derived from a pretreatment imaging study is un-
likely to offer a predictor of pathological response that is
robust enough to drive treatment decision-making. Anobvious limitation of the studies that used FDG-PET is the
heavy reliance on the SUVmax within the tumour e a single-
pixel measure that is subject to considerable noise effect
[63]. This is in keeping with the observation that oesopha-
geal tumours were more likely to respond to CRT if the
number of pixels with a high SUV value was small [36],
suggesting that noise effect could artiﬁcially elevate the
SUVmax. There is an emerging trend to utilise much more of
the information that is included in the scan rather than a
single point value. Approaches including total glycolytic
volume [63], texture features (descriptivemeasures of tracer
uptake heterogeneity) [17,36] and even the simple method
of combining tumour diameter with SUVmax to produce a
‘diameter-SUV index’ [31] may offer better predictive and
prognostic utility. Using a support vector model that incor-
porated a number of features, the treatment outcome for all
20 patients treated with CRT for oesophageal cancer could
be accurately predicted when all features, including FDG-
PET textural analysis, were taken into account [64].
The timing of the FDG-PET response assessment is
probably crucial. Failure of post-CRT functional imaging to
accurately predict the pathological response may be due to
post-CRToesophagitis [25] or because cell ‘stunning’ effects,
which have nothing to do with tumour cell viability [18],
confound the picture. Some experts therefore advocate re-
imaging earlier in the course of treatment as the onset of
treatment-associated oesophagitis is around 2 weeks
[65,66] and as the reduction in FDG uptake at this time
point may be more representative of cell death rather than
stunning. Moreover, deferring reassessment until after CRT
has been completed does not give the opportunity of ther-
apeutic intervention, such as radiotherapy dose escalation,
in those who are failing to have an optimal response.
It is clear that if FDG-PET is to be used for radiotherapy
planning, it should be carried out as close to the planning
computed tomography scan as possible [59]. Disease pro-
gression from the time of diagnostic scanning to treatment
planning could lead to the failure of inclusion of the positive
lymph nodes in the treatment volume or progressing with a
radical treatment plan in the presence of metastatic disease.
The inclusion of hybrid PET/computed tomography scan-
ning into routine planning computed tomography is worthy
of consideration.
The method of using functional imaging to derive GTVs
needs to be standardised. Some trials have used ‘side by
side’/sequential viewing of images [55,57], whereas others
have either relied upon image registration software [51,54]
or using hybrid PET/computed tomography scanners [52].
The conformality index is often used to describe the reli-
ability of a method of target volume deﬁnition compared
with a current standard. This could be potentially prob-
lematic in upper gastrointestinal malignancies, particularly
pancreatic cancer, where in the presence of a large, physi-
ologically quiescent, stromal component to the tumour, the
conformality index will always be low despite the func-
tional imaging test identifying a region of interest that may
contain all viable tumour cells.
The investigation of PET tracers that give information on
a variety of speciﬁc physiological processes, such as
J.M. Wilson et al. / Clinical Oncology 26 (2014) 581e596594hypoxia, may be beneﬁcial. The use of FDG-PET has a good
scientiﬁc basis, in addition to being a pragmatic choice
because of wide availability and relatively low costs. In a
preclinical model, FDG-avid tumours required an increase
in radiation dose to improved local control rates, whereas
tumours with low FDG-avidity did not beneﬁt from an
increased radiation dose [67], suggesting that FDG-PET may
be an appropriate means of deﬁning an area that would
beneﬁt from dose boosting. Targeting hypoxic areas within
the GTV is attractive given that hypoxia leads to chemo-
radioresistance. Local treatment failure is an important
consideration, both for oesophageal and pancreatic tu-
mours, so dose-escalating a hypoxic subvolume is ideolog-
ically appealing. Other hypoxic tracers, such as 18F-
misonidazole or 64Cu-ATSM (diacetyl-bis (N4-
methylthiosemicarbazone)) should be investigated, as
they may increase conﬁdence in PET-derived hypoxic vol-
umes. In preclinical oesophageal cancer models, FLT uptake
has been shown to be a rapidly responding marker of
response to CRT [68]. Using FLT as a PET tracer seems to be
attractive, as cellular retention of FLT relies upon phos-
phorylation by tyrosine kinase 1, which is only expressed in
late G1 and S phase. Targeting only proliferating cells may
be beneﬁcial and may improve some of the poor predictive
and prognostic utility associated with FDG uptake.
A greater understanding of the need for four-
dimensional PET scanning is required. There can be
considerable movement of oesophageal tumours
throughout the respiratory cycle, particularly in the cra-
niocaudal direction in lower thoracic tumours [69]. Data
acquisition in a static PET scan is a slow process (over mi-
nutes). Uptake detection is therefore averaged throughout
the time of acquisition and across the whole respiratory
cycle. This will be of particular relevance if individualised
thresholds are used. Four-dimensional PET imaging may
allow a greater conﬁdence in individual voxel SUV values
and in boundaries of transition between tracer uptake
thresholds. Pancreatic tumours move throughout the
breathing cycle. No studies to date have investigated four-
dimensional PET in pancreatic cancer. The role of PET/MRI
also remains uncertain.Conclusion
Further studies are required to increase the conﬁdence in
the predictive and prognostic power of functional imaging
in upper gastrointestinal malignancies. A multimodality,
multiparametric assessment of the tumours at more than
one time point to increase the likelihood of ﬁnding pre-
dictive indices should be systematically explored. Attempts
should bemade to reduce the time from imaging to the start
of CRT. The imaging modality used should give information
about a physiological process that is associated with treat-
ment resistance. With increased conﬁdence in this imaging
modality, the functional imaging could then be used for
biological target volume deﬁnition. Delivering a higher
radiotherapy dose to areas of the tumour that are less likely
to respond, or integrating physiological modulating agentsinto the CRT regimen, may increase the likelihood of pCR
without increasing treatment toxicity. This approachwould,
however, requires a robust means of risk stratiﬁcation that
can be carried out early in the treatment schedule.Acknowledgments
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